About Us

Our Mission

We are a clinical stage biotech company committed to protecting patients’ brain health and changing outcomes for a broad range of neurodegenerative diseases through best-in-class diagnostic tools and novel therapies.

Our name, APRINOIA, merges the Latin word for sunlight, “apricum,” with the Greek suffix for the mind, “noia.” Our name reflects our mission—to shed light on ways to better diagnose and treat these dreaded neurodegenerative disorders with a vision that these novel diagnostic tools together with targeted therapies will offer a better future for our patients.

Our Team

scientist in lab - our partners

Our Partners

We have aligned with renowned organizations and elite research institutions to bring precision medicine to neuroscience and push boundaries in the treatment of neurodegenerative diseases. We will continue to expand our partnerships to further develop therapeutic assets through late-phase clinical studies and commercialization.

Research and Development Partners

InSilico Medicine
The Michael J. Fox Foundation

Finance Partners

DAOL Investment
Daiwa
Company K Partners
ShangPharma Innovation
taian
DongCheng Pharmaceutical
Daiwa
In Manus Mundus